PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression

Targeted therapy with small molecules directed at essential survival pathways in leukemia represents a major advance, including the phosphatidylinositol-3′-kinase (PI3K) p110δ inhibitor idelalisib. Here, we found that genetic inactivation of p110δ (p110δ(D910A/D910A)) in the Eμ-TCL1 murine chronic l...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Clin Invest
Main Authors: Dong, Shuai, Harrington, Bonnie K., Hu, Eileen Y., Greene, Joseph T., Lehman, Amy M., Tran, Minh, Wasmuth, Ronni L., Long, Meixiao, Muthusamy, Natarajan, Brown, Jennifer R., Johnson, Amy J., Byrd, John C.
Format: Artigo
Sprog:Inglês
Udgivet: American Society for Clinical Investigation 2018
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6307940/
https://ncbi.nlm.nih.gov/pubmed/30457982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI99386
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker